Ellingson BM, Wen PY, Cloughesy TF. Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma. Neuro Oncol 2023 May 11:noad085. doi: 10.1093.
PMID: 37167013